ethyl glutarate N-hydroxysuccinimide ester | 1001404-45-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl glutarate N-hydroxysuccinimide ester
• 英文别名: ethyl glutarate NHS ester；2,5-Dioxopyrrolidin-1-yl ethyl glutarate；5-O-(2,5-dioxopyrrolidin-1-yl) 1-O-ethyl pentanedioate
• CAS: 1001404-45-0
• 化学式: C₁₁H₁₅NO₆
• 分子量: 257.243
• InChiKey: LFXCCXLCNMOCPP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  90
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl glutarate N-hydroxysuccinimide ester 在 三氟乙酸 、 三乙胺 作用下， 以 二氯甲烷 、 四氢呋喃 为溶剂， 反应 4.0h， 以70%的产率得到LysEtGlutar-H(2,2)-1,2-HOPOBn
  参考文献：
  名称：

  WO2008/8797

  摘要：

  公开号：
• 作为产物：
  描述：

  N-羟基丁二酰亚胺 、 戊二酸 在 N,N'-二环己基碳二亚胺 作用下， 生成 ethyl glutarate N-hydroxysuccinimide ester
  参考文献：
  名称：

  WO2008/63721

  摘要：

  公开号：

文献信息

• LUMINESCENT MACROCYCLIC LANTHANIDE COMPLEXES
  申请人：Raymond Kenneth N.

  公开号：US20080213917A1

  公开（公告）日：2008-09-04

  The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands.

  本发明提供了一种新的大环化合物类别，以及由金属（例如镧系金属）离子和本发明中化合物形成的配合物。首选的配合物在水介质中表现出高稳定性以及高量子产率的镧系离子发光特性，无需使用次级活化剂。首选化合物在其大环结构中包含羟基异苯酰胺基团，并以惊人的低非特异性结合多种多肽（如抗体和蛋白质）以及高动力学稳定性为特征。这些特征使它们与已知的开放结构配体有所区别。
• GEL COMPOSITION FOR CELLULAR ADHESION INHIBITION
  申请人：Zong Xinhua

  公开号：US20070031498A1

  公开（公告）日：2007-02-08

  The invention includes compositions for inhibiting cellular adhesion, methods of preparation of such compositions, and methods for preventing cell adhesion at a surgical site comprising application of such compositions. The compositions generally comprise a cellular adhesion inhibitory agent, such as dextran sulfate, and a crosslinked hydrogel matrix, preferentially physically entrapping the adhesion inhibitory agent. The hydrogel matrix can include a first gel component, such as an electrophilically functionalized polyethylene glycol polymer, and at least one additional gel component, preferably nucleophilically functionalized, and preferentially selected from the group consisting of polyethylene glycol polymers, polypeptides, and polysaccharides. The compositions are useful for delivering the cellular adhesion inhibitory agent to a site in need of adhesion inhibition and providing either immediate or metered delivery of the inhibitory agent.
• Method of Relieving, Improving, Preventing or Treating Xerostomia
  申请人：SUNBIO INC.

  公开号：US20140155457A1

  公开（公告）日：2014-06-05

  Provided is a method of relieving, improving, preventing or treating xerostomia including applying an oral cavity composition including a polyethylene glycol (PEG) derivative whose reactor is modified to form a covalent bond with an epithelial cell of the oral cavity. An oral moisturizing effect and moisture persistency are increased and the method is effective against xerostomia due to aging or disease.
• POLETHYLENE GLYCOL HYDROGEL INJECTION
  申请人：SUNBIO INC.

  公开号：US20170340774A1

  公开（公告）日：2017-11-30

  The present invention relates to a polyethylene glycol hydrogel injection, and, more particularly, to an injection to be administered into a joint (a synovial joint cavity) for the improvement of symptoms of arthritis by containing two separate buffer solutions, wherein a solution (1) contains a polyethylene glycol derivative with an electrophilic functional group and a buffer of pH 3.5 to 6, and a solution (2) contains a polyethylene glycol derivative with a nucleophilic functional group, hyaluronic acid, and a buffer of pH 7.5 to 11. The injection of the present invention is highly biocompatible and long-lasting in the joint, showing the efficacy of pain relief, cartilage protection, and inhibition of inflammation, thus offering the effective prevention and treatment of arthritis.
• US8173800B2
  申请人：——

  公开号：US8173800B2

  公开（公告）日：2012-05-08